Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood. Stream infection isolates caused by non-enteric gram-negative bacilli: Occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes

Diagnostic Microbiology and Infectious Disease

Volumn 29, Issue 3, 1997, Pages 187-192

  Jones, Ronald N ^a   Pfaller, Michael A ^a   Marshall, Steven A ^a   Hollis, Richard J ^a   Wilke, Werner W ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; OFLOXACIN; PIPERACILLIN; TAZOBACTAM; TOBRAMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BLOOD; CONTROLLED STUDY; HOSPITAL INFECTION; INFECTION CONTROL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA; UNITED STATES;

EID: 0030668767     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(97)81808-1     Document Type: Article

References (15)

1. Burwen DR, Banerjee SN, Gaynes RP, and the National Nosocomial Infectious Surveillance System (1994) Ceftazidime resistance among selected nosocomial Gram-negative bacilli in the United States. J Infect Dis 170:1622-1625.
2. Cisterna R, Ezpeleta C, Sota M, SEIMC Group (1997) Bacteremia in Spain. A Multicenter Study. Abstr. P874. Lausanne, Switzerland: ECCMID.
3. Emori TG, Gaynes RP (1993) An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 6:428-442.
4. Gransden WR, Leibovici L, Eykyn SJ, Pitlik SD, Samra Z, Konisberger H, Drucker M, Phillips I (1995) Risk factors and a clinical index for diagnosis of Pseudomonas aeruginosa bacteremia. J Clin Microbiol Infect 1:119-123.
5. Jones RN, Kehrberg EN, Erwin ME, Anderson SC, and the Fluorquinolone Resistance Surveillance Group (1994) Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. I. Study on the threat of emerging resistance: Real or perceived? Diagn Microbiol Infect Dis 19:203-215.
6. Jones RN, Marshall SA, Pfaller MA, Wilke WW, Hollis RJ, Erwin ME, Edmond MB, Wenzel RP, and the SCOPE Hospital Study Group (1997) Nosocomial enterococcal blood stream infections in the SCOPE Program: Antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. Diagn Microbiol Infect Dis. In press.
7. Marshall SA, Aldridge KE, Allen SD, Jones RN, Fuchs PC, Gerlach EH (1995) Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers: A reevaluation after 5 years. Diagn Microbiol Infect Dis 21:153-168.
8. Murray PR, Cantrell HF, Lankford RB, and the In Vitro Susceptibility Surveillance Group (1994) Multicenter evaluation of the in vitro activity of piperacillintazobactam compared with 11 selected β-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic Gram-positive and Gram-negative bacteria. Diagn Microbiol Infect Dis 19:111-120.
9. National Committee for Clinical Laboratory Standards (1997) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved Standard M7-A4. Wayne, PA: National Committee for Clinical Laboratory Standards.
10. Pfaller MA, Wendt C, Hollis RJ, Wenzel RP, Fritschel SJ, Neubauer JJ, Herwaldt LA (1996) Comparative evaluation of an automated ribotying system versus pulsedfield gel electrophoresis for epidemiological typing of clinical isolates of Escherichia coli and Pseudomonas aeruginosa from patients with recurrent Gram-negative bacteremia. Diagn Microbiol Infect Dis 25:1-8.
11. Pfaller MA, Jones RN, Marshall SA, Coffman SL, Hollis RJ, Edmond MB, Wenzel RP (1997) Inducible Amp C β-lactamase producing Gram-negative bacilli from blood stream infections: Frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagn Microbiol Infect Dis. In press.
12. Rasmussen BA, Bush K (1997) Carbapenem-hydrolyzing β-lactamases. Antimicrob Agents Chemother 41:223-232.
13. IMP)in Gram-negative rods resistant to broad-spectrum β-lactams. J Clin Microbiol 34:2909-2913.
14. Tankovic J, Legrand P, DeGatines G, Chemineau V, Brun-Buisson C, Duval J (1994) Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic methods. J Clin Microbiol 32:2677-2681.
15. Visalli MA, Jacobs MR, Moore TD, Renzi FA, Appelbaum PC (1997) Activities of β-lactams against Acinetobacter genospecies as determined by agar dilution and E-test MIC methods. Antimicrob Agents Chemother 41:767-770.